Anacetrapib: A New Weapon Against Dyslipidemia

Title: Anacetrapib: A New Weapon Against Dyslipidemia

Volume: 6 Issue: 4

Author(s): Georgios Aperis, Christos Paliouras, Eirini Tsampikaki, Nikolaos Papakonstantinou and Polichronis Alivanis

Affiliation:

Keywords: Anacetrapib, cholesteryl, ester, transfer-protein, inhibitor, Dyslipidemia, cardiovascular disease, cholesterol, blood pressure, plasma

Abstract: Anacetrapib is a cholesteryl-ester-transfer-protein (CETP) inhibitor, a new class of experimental drugs in the treatment of primary hypercholesterolemia and dyslipidaemia associated with the metabolic syndrome. One of the major advantages of this agent is, apart from the significant decrease in LDL-C it produces a substantial increase in HDL-C. Phase I, II, and III clinical trials have shown that anacetrapib is safe alone or in combination with statins. However, longterm clinical trials are required in order to assess whether it reduces mortality in individuals at high-risk of cardiovascular disease.

Cite this article as:

Aperis Georgios, Paliouras Christos, Tsampikaki Eirini, Papakonstantinou Nikolaos and Alivanis Polichronis, Anacetrapib: A New Weapon Against Dyslipidemia, Current Clinical Pharmacology 2011; 6 (4) . https://dx.doi.org/10.2174/157488411798375949